News about Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has raised its dividend for 64 straight years, yet a plain S&P 500 index fund beat the stock over the past decade. A $1,000 investment 10 years ago with reinvested dividends would be worth $2,957.10 today, about $703 of it from dividends, versus $3,593.10 for the S&P 500 over the same period, excluding dividends. In the third quarter of 2026, about $7 billion in charges for a proposed talc settlement and two deals cut reported EPS to $0.09, while adjusted EPS was $2.59. The company expects $21 billion in free cash flow this year, but net debt is about $28 billion, and two recent deals are expected to cut 2027 adjusted EPS by $1.36; the article warns that if talc payments eat into free cash flow, dividend increases could shrink.

Johnson & Johnson has launched the Shockwave C2 Aero Fly Coronary IVL catheter in the U.S., designed to treat calcified coronary artery lesions in half the time of previous coronary IVL devices. The catheter delivers pulses at double the speed and cuts pause time between cycles to five seconds, reducing treatment time from 230 seconds to 115 seconds and lowering patients’ ischemic time. Coronary artery disease is the leading cause of death globally, affecting an estimated 315 million people worldwide. The device will be showcased at TCT 2026 in San Diego, California, from October 31 to November 3, 2026.

The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.